ESC Congress 2020 – The Digital Experience

Elevated troponin spells worse outcomes in COVID-19

Elvira Manzano, 20201002104000

Elevated troponin T levels at hospital admission may be a harbinger of adverse outcomes in COVID-19 but could help risk-stratify patients, according to a new study. Those with cardiovascular disease (CVD) are also more vulnerable than those without, bolstering the suspected link between.

Omitting clopidogrel the better strategy post-TAVI

Elvira Manzano, 20200929024000

The use of aspirin alone following TAVI* significantly reduced bleeding vs aspirin plus clopidogrel in the POPular TAVI study. This benefit came without increasing thromboembolic events, effectively positioning aspirin as the better antithrombotic strategy after TAVI.

Evolocumab scores big in paediatric HeFH

Elvira Manzano, 20200928141100

Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.

Old drug, new tricks: Colchicine for chronic coronary disease

Roshini Claire Anthony, 20200925190001

Low-dose colchicine reduced the risk of multiple cardiovascular (CV) outcomes in patients with chronic coronary disease, according to the LoDoCo2* trial presented at ESC 2020.

Empagliflozin reduces CV death, HF hospitalization in HFrEF patients

Roshini Claire Anthony, 20200923200001

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Dapagliflozin excels in chronic kidney disease, even in patients without diabetes

DAPA-CKD heralds a new era for dapagliflozin in kidney disease

Pearl Toh, 20200923143500

Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.

Can coronary plaque EVAPORATE with prescription-grade EPA?

Audrey Abella, 20200916100000

The final results of EVAPORATE* reinforce the plaque-regressing potential of icosapent ethyl (IPE) in patients on statins for elevated triglycerides.

Long naps may increase CVD, all-cause mortality risks

Elaine Soliven, 20200915103510

Individuals who reported a long nap duration of 60 minutes/day had a higher risk of cardiovascular disease (CVD) and all-cause mortality than those who did not take any daytime naps, according to a study presented at ESC 2020.

BRACE CORONA advocates continuing ACEis/ARBs in mild-to-moderate COVID-19

Roshini Claire Anthony, 20200914200001

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Rhythm vs rate control in AF: A win finally?

Pearl Toh, 20200912140000

Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.